Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score
Autor(a) principal: | |
---|---|
Data de Publicação: | 2001 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | São Paulo medical journal (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802001000400005 |
Resumo: | CONTEXT: Multiple genetic and epigenetic factors have been implicated in the oncogenesis and progression of prostate cancer. The major difficulty is in that the clinical management stems from the reality that reliable and accurate prognostic biomarkers are not available and that effective treatment regimens forming hormone-resistant prostate cancers are yet to be developed. Among the most important regulators of apoptosis and programmed cell death is the bcl-2 gene and its related proteins. Elevated levels of bcl-2 protein may contribute to the progression of prostate cancers to a metastatic and hormone-insensitive state characterized by poor responses to chemotherapy. OBJECTIVE: To characterize the expression of bcl-2 proteins as a prognostic factor in humans. DESIGN: A retrospective approach. SETTING: Urology section, Federal University of São Paulo. DIAGNOSTIC TEST USED: Immunohistochemical analysis using bcl-2 protein antibody and normal staining by hematoxylin-eosin. MAIN MEASUREMENTS: Prognostic relations and protein expression were evaluated considering the total sample (28) divided into two groups, high (8 to 10) and low (2 to 4), separated according to the histological differentiation grade (Gleason score) with 10 and 18 samples, respectively. RESULTS: The differentiation of grade into two groups separated according to the Gleason score in low and high types presented different bcl-2 expression (P < 0.001). CONCLUSION: The higher frequency of bcl-2 immunostaining in tumor samples was observed in association with more advanced Gleason scores and suggests that an increase in the ratio of this anti-apoptotic protein often occurs during progression of prostate cancers. |
id |
APM-1_36a4151cfd971e3a2f9a954a43ce53ef |
---|---|
oai_identifier_str |
oai:scielo:S1516-31802001000400005 |
network_acronym_str |
APM-1 |
network_name_str |
São Paulo medical journal (Online) |
repository_id_str |
|
spelling |
Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason scorebcl-2ProstateProstate adenocarcinomaApoptosisCONTEXT: Multiple genetic and epigenetic factors have been implicated in the oncogenesis and progression of prostate cancer. The major difficulty is in that the clinical management stems from the reality that reliable and accurate prognostic biomarkers are not available and that effective treatment regimens forming hormone-resistant prostate cancers are yet to be developed. Among the most important regulators of apoptosis and programmed cell death is the bcl-2 gene and its related proteins. Elevated levels of bcl-2 protein may contribute to the progression of prostate cancers to a metastatic and hormone-insensitive state characterized by poor responses to chemotherapy. OBJECTIVE: To characterize the expression of bcl-2 proteins as a prognostic factor in humans. DESIGN: A retrospective approach. SETTING: Urology section, Federal University of São Paulo. DIAGNOSTIC TEST USED: Immunohistochemical analysis using bcl-2 protein antibody and normal staining by hematoxylin-eosin. MAIN MEASUREMENTS: Prognostic relations and protein expression were evaluated considering the total sample (28) divided into two groups, high (8 to 10) and low (2 to 4), separated according to the histological differentiation grade (Gleason score) with 10 and 18 samples, respectively. RESULTS: The differentiation of grade into two groups separated according to the Gleason score in low and high types presented different bcl-2 expression (P < 0.001). CONCLUSION: The higher frequency of bcl-2 immunostaining in tumor samples was observed in association with more advanced Gleason scores and suggests that an increase in the ratio of this anti-apoptotic protein often occurs during progression of prostate cancers.Associação Paulista de Medicina - APM2001-07-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802001000400005Sao Paulo Medical Journal v.119 n.4 2001reponame:São Paulo medical journal (Online)instname:Associação Paulista de Medicinainstacron:APM10.1590/S1516-31802001000400005info:eu-repo/semantics/openAccessHering,Flávio Luiz OrtizLipay,Mônica Vannucci NunesLipay,Marco Aurélio SilvaRodrigues,Paulo Roberto TeixeiraNesralah,Luciano JoséSrougi,Migueleng2001-08-03T00:00:00Zoai:scielo:S1516-31802001000400005Revistahttp://www.scielo.br/spmjhttps://old.scielo.br/oai/scielo-oai.phprevistas@apm.org.br1806-94601516-3180opendoar:2001-08-03T00:00São Paulo medical journal (Online) - Associação Paulista de Medicinafalse |
dc.title.none.fl_str_mv |
Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score |
title |
Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score |
spellingShingle |
Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score Hering,Flávio Luiz Ortiz bcl-2 Prostate Prostate adenocarcinoma Apoptosis |
title_short |
Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score |
title_full |
Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score |
title_fullStr |
Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score |
title_full_unstemmed |
Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score |
title_sort |
Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score |
author |
Hering,Flávio Luiz Ortiz |
author_facet |
Hering,Flávio Luiz Ortiz Lipay,Mônica Vannucci Nunes Lipay,Marco Aurélio Silva Rodrigues,Paulo Roberto Teixeira Nesralah,Luciano José Srougi,Miguel |
author_role |
author |
author2 |
Lipay,Mônica Vannucci Nunes Lipay,Marco Aurélio Silva Rodrigues,Paulo Roberto Teixeira Nesralah,Luciano José Srougi,Miguel |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Hering,Flávio Luiz Ortiz Lipay,Mônica Vannucci Nunes Lipay,Marco Aurélio Silva Rodrigues,Paulo Roberto Teixeira Nesralah,Luciano José Srougi,Miguel |
dc.subject.por.fl_str_mv |
bcl-2 Prostate Prostate adenocarcinoma Apoptosis |
topic |
bcl-2 Prostate Prostate adenocarcinoma Apoptosis |
description |
CONTEXT: Multiple genetic and epigenetic factors have been implicated in the oncogenesis and progression of prostate cancer. The major difficulty is in that the clinical management stems from the reality that reliable and accurate prognostic biomarkers are not available and that effective treatment regimens forming hormone-resistant prostate cancers are yet to be developed. Among the most important regulators of apoptosis and programmed cell death is the bcl-2 gene and its related proteins. Elevated levels of bcl-2 protein may contribute to the progression of prostate cancers to a metastatic and hormone-insensitive state characterized by poor responses to chemotherapy. OBJECTIVE: To characterize the expression of bcl-2 proteins as a prognostic factor in humans. DESIGN: A retrospective approach. SETTING: Urology section, Federal University of São Paulo. DIAGNOSTIC TEST USED: Immunohistochemical analysis using bcl-2 protein antibody and normal staining by hematoxylin-eosin. MAIN MEASUREMENTS: Prognostic relations and protein expression were evaluated considering the total sample (28) divided into two groups, high (8 to 10) and low (2 to 4), separated according to the histological differentiation grade (Gleason score) with 10 and 18 samples, respectively. RESULTS: The differentiation of grade into two groups separated according to the Gleason score in low and high types presented different bcl-2 expression (P < 0.001). CONCLUSION: The higher frequency of bcl-2 immunostaining in tumor samples was observed in association with more advanced Gleason scores and suggests that an increase in the ratio of this anti-apoptotic protein often occurs during progression of prostate cancers. |
publishDate |
2001 |
dc.date.none.fl_str_mv |
2001-07-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802001000400005 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802001000400005 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/S1516-31802001000400005 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Associação Paulista de Medicina - APM |
publisher.none.fl_str_mv |
Associação Paulista de Medicina - APM |
dc.source.none.fl_str_mv |
Sao Paulo Medical Journal v.119 n.4 2001 reponame:São Paulo medical journal (Online) instname:Associação Paulista de Medicina instacron:APM |
instname_str |
Associação Paulista de Medicina |
instacron_str |
APM |
institution |
APM |
reponame_str |
São Paulo medical journal (Online) |
collection |
São Paulo medical journal (Online) |
repository.name.fl_str_mv |
São Paulo medical journal (Online) - Associação Paulista de Medicina |
repository.mail.fl_str_mv |
revistas@apm.org.br |
_version_ |
1754209260384813056 |